Literature DB >> 9376597

Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity.

M M Ott1, J Bartkova, J Bartek, A Dürr, L Fischer, G Ott, H K Müller-Hermelink, H Kreipe.   

Abstract

The cell cycle regulatory protein cyclin D1 is essential for G1-S phase transition in several epithelial and mesenchymal tissues but is apparently not essential in normal mature B cells. An overexpression of cyclin D1 is induced by the chromosomal translocation t(11;14)(q13;q32), which characterizes non-Hodgkin's lymphomas (NHLs) of mantle cell type. We studied 26 cases of mantle cell lymphoma (MCL) for the expression of cyclins D1 and D3. A total of 23 lymphomas showed a nuclear staining for cyclin D1, whereas reactive B cells of residual germinal centers were constantly negative. When compared with cyclin D3, an inverse staining pattern emerged. Whereas the B cells of residual germinal centers reacted strongly positive for cyclin D3, there was low or missing expression of cyclin D3 in MCL cells. In other B-cell lymphomas (n = 55), including chronic lymphocytic leukemia, low-grade lymphomas of mucosa-associated lymphatic tissue, follicular lymphomas, and diffuse large B-cell lymphomas, no cyclin D1 expression could be detected and 89% of these cases displayed cyclin D3 positivity. Lymphoma cell lines harboring the t(11;14) showed cyclin D1 protein but no or very low levels of cyclin D3; three other B-cell lines, a T-cell line, and peripheral blood lymphocytes strongly expressed cyclin D3 and reacted negatively for cyclin D1. We conclude that the chromosomal translocation t(11;14) leads to an abnormal protein expression of cyclin D1 in the tumor cells of MCL and induces a consecutive downregulation of cyclin D3. In contrast to other B-NHLs, cyclin D1 and D3 expression in MCL is not related to the growth fraction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9376597

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders.

Authors:  E Matutes
Journal:  J Clin Pathol       Date:  2002-03       Impact factor: 3.411

2.  Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).

Authors:  G Pruneri; S Fabris; L Baldini; N Carboni; S Zagano; M A Colombi; G Ciceri; L Lombardi; M Rocchi; R Buffa; A T Maiolo; A Neri
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

3.  Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.

Authors:  Kai Fu; Dennis D Weisenburger; Timothy C Greiner; Sandeep Dave; George Wright; Andreas Rosenwald; Michael Chiorazzi; Javeed Iqbal; Stefan Gesk; Reiner Siebert; Daphne De Jong; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; German Ott; Bhavana J Dave; Warren G Sanger; Lynette M Smith; Lisa Rimsza; Rita M Braziel; H Konrad Müller-Hermelink; Elias Campo; Randy D Gascoyne; Louis M Staudt; Wing C Chan
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

4.  Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.

Authors:  Nousheen Samad; Anas Younes
Journal:  Onco Targets Ther       Date:  2010-09-07       Impact factor: 4.147

5.  Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas.

Authors:  N S Aguilera; K E Bijwaard; B Duncan; A E Krafft; W S Chu; S L Abbondanzo; J H Lichy; J K Taubenberger
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

6.  CyclinD1/CyclinD3 ratio by real-time PCR improves specificity for the diagnosis of mantle cell lymphoma.

Authors:  Carol D Jones; Katherine H Darnell; Roger A Warnke; James L Zehnder
Journal:  J Mol Diagn       Date:  2004-05       Impact factor: 5.568

7.  Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.

Authors:  Varun V Prabhu; Mala K Talekar; Amriti R Lulla; C Leah B Kline; Lanlan Zhou; Junior Hall; A Pieter J Van den Heuvel; David T Dicker; Jawad Babar; Stephan A Grupp; Mathew J Garnett; Ultan McDermott; Cyril H Benes; Jeffrey J Pu; David F Claxton; Nadia Khan; Wolfgang Oster; Joshua E Allen; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2018-02-19       Impact factor: 4.534

Review 8.  Cell kinetics and cell cycle regulation in lymphomas.

Authors:  L Leoncini; S Lazzi; C Bellan; P Tosi
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

9.  miR-30e* is overexpressed in prostate cancer and promotes NF-κB-mediated proliferation and tumor growth.

Authors:  Shawn M Egan; Ellen Karasik; Leigh Ellis; Sandra O Gollnick
Journal:  Oncotarget       Date:  2017-06-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.